India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
India had a 38% reduction in Tuberculosis deaths in comparison to 35% globally. This has…
Indian boxing celebrated a landmark moment at the 2026 Youth Olympic Games in Dakar, Senegal,…
Another milestone has been reached with Japan placing the first orders for electronically powered train…
Maruthi R. Akella, an aerospace scientist and control systems engineer from the University of Texas…
President Droupadi Murmu distributed the National Sports Awards 2025 on 13th November 2026. A total…
A global Microsoft outage on November 12, 2026 affected a range of services including Outlook,…